Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

1.0K
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
1.0K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

398
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormone replacement therapy: consensus and controversies.

Panminerva medica·2014
Same author

Individualizing hormone-therapy according to cardiovascular risk.

Minerva medica·2012
Same author

Comparison of estrogen and androgen levels after oral estrogen replacement therapy.

The Journal of reproductive medicine·2002
Same author

Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

Annals of internal medicine·2001
Same author

Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.

Fertility and sterility·2001
Same author

Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women.

Menopause (New York, N.Y.)·2001
Same journal

High grade cervical intraepithelial neoplasia positive biopsy: the importance of accurate pre-operative workup.

Minerva ginecologica·2021
Same journal

Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: a multicenter clinical trial.

Minerva ginecologica·2020
Same journal

[Advisory Board Italiano sulla sindrome dell'ovaio policistico (PCOS): dalle osservazioni all'esperienze cliniche sull'uso del mioinositolo (MYO) e dell'acido alfa-lipoico (ALA) per migliorare i quadri della sindrome].

Minerva ginecologica·2020
Same journal

Update on new imaging technologies in sentinel node detection.

Minerva ginecologica·2020
Same journal

Postoperative pelvic dysfunctions associated with the reconstruction of the pelvic floor.

Minerva ginecologica·2020
Same journal

The role of sentinel-node biopsy in ovarian cancer.

Minerva ginecologica·2020
See all related articles

Related Experiment Video

Updated: May 4, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.1K

Individualizing hormone-therapy according to cardiovascular risk.

D Shoupe1

  • 1Reproductive Endocrinology and Infertility Obstetrics and Gynecology Keck School of Medicine at University of Southern California , Los Angeles, CA, USA - shoupe@usc.edu.

Minerva Ginecologica
|December 19, 2013
PubMed
Summary
This summary is machine-generated.

Hormone therapy offers benefits like reduced cardiovascular disease (CVD) and fractures, but risks vary by age and health. Low-dose transdermal therapy may be safer for women with CVD risk factors.

More Related Videos

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.2K

Related Experiment Videos

Last Updated: May 4, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.1K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.2K

Area of Science:

  • Reproductive Medicine
  • Cardiovascular Health
  • Gerontology

Background:

  • Hormone therapy (HT) is sought by women for benefits including cardiovascular disease (CVD) protection, fracture prevention, and reduced mortality.
  • HT initiation requires careful risk-benefit analysis, considering individual factors like age and cardiovascular risk.
  • Specific patient groups, such as those with existing CVD or immobilization, may face contraindications for HT.

Purpose of the Study:

  • To evaluate the risk-benefit profile of hormone therapy in diverse women's health contexts.
  • To inform clinical decisions regarding hormone therapy initiation and continuation.
  • To identify specific patient populations who may benefit most or face increased risks from hormone therapy.

Main Methods:

  • Review of existing literature on hormone therapy efficacy and safety.
  • Analysis of risk factors for cardiovascular disease (CVD) and other conditions in relation to hormone therapy.
  • Consideration of patient demographics such as age and menopausal status.

Main Results:

  • Low-dose transdermal hormone therapy can mitigate risks associated with oral formulations for women with cardiovascular risk factors.
  • Hormone replacement is generally contraindicated for women with recent cardiovascular events, thromboembolic disease, immobilization, or severe peripheral arterial disease.
  • A favorable benefit-to-risk ratio for HT is recognized in healthy, low-risk women initiating therapy under age 60 or within 10 years of menopause.

Conclusions:

  • Hormone therapy offers significant benefits but necessitates individualized risk assessment.
  • Transdermal, low-dose HT may be a safer option for women with cardiovascular disease (CVD) risk factors.
  • Careful consideration of age, menopausal status, and cardiovascular risk factors is crucial for optimal hormone therapy outcomes.